Yuhong Li

Academic / Other · 11 registered clinical trials.

Status	Trial	Phase	Started
Completed	Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients. Pancreatic Cancer Resectable	Phase 2	2020-01-31
Completed	Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC Metastatic Colorectal Cancer	Phase 2	2020-01-31
Completed	Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	Phase 2	2016-10-01
Completed	Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment Esophageal Squamous Cell Carcinoma	Phase 2	2016-08-01
Completed	Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Esophageal Squamous Cell Carcinoma	Phase 2	2015-01-01
Completed	Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer Colorectal Cancer, Chemotherapy-induced Neutropenia	Phase 3	2014-09-01
Unknown	A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Met Metastatic Colorectal Cancer	Phase 3	2014-03-01
Completed	Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Fail Esophageal Squamous Cell Carcinoma	Phase 2	2013-10-01
Completed	S-1 in Combination With Abraxane in Treating Cholangiocarcinoma Cholangiocarcinoma	Phase 2	2013-08-01
Completed	mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer Metastatic Pancreatic Cancer	Phase 2	2013-02-01
Completed	FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma Advanced Esophageal Carcinoma	Phase 2	2012-03-01